Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

Nature communications·2026
Same author

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

Cancer discovery·2026
Same author

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

Nature communications·2026
Same author

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.

Targeted oncology·2026

Related Experiment Video

Updated: Apr 12, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Classifying Cancers Based on T-cell Infiltration and PD-L1.

Michele W L Teng1, Shin Foong Ngiow2, Antoni Ribas3

  • 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia. mark.smyth@qimrberghofer.edu.au michele.teng@qimrberghofer.edu.au.

Cancer Research
|May 16, 2015
PubMed
Summary

Cancer immunotherapy is a promising cancer treatment. Understanding tumor microenvironments and immune evasion strategies can help design better combination therapies.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

Related Experiment Videos

Last Updated: Apr 12, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Cancer immunotherapy is emerging as a critical treatment modality.
  • Tumors employ diverse strategies to evade immune responses.
  • The tumor microenvironment plays a crucial role in treatment efficacy.

Purpose of the Study:

  • To review the proposed stratification of tumor microenvironments.
  • To discuss the latest research on cancer immunology.
  • To guide the rational design of combination cancer therapies.

Main Methods:

  • Literature review of cancer immunotherapy research.
  • Analysis of tumor microenvironment classifications.
  • Synthesis of recent findings in tumor immunology.

Main Results:

  • Four distinct tumor microenvironment types are proposed based on immune cell infiltration and PD-L1 expression.
  • Recent data provide insights into tumor immune evasion mechanisms.
  • Understanding these factors is key to developing effective combination therapies.

Conclusions:

  • The stratification of tumor microenvironments offers a framework for treatment selection.
  • Advances in tumor immunology are paving the way for novel combination strategies.
  • Rational design of combination immunotherapies holds significant promise for future cancer treatment.